Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (221-230 of 539) with videos related to

Pageof 54
Sort By:
Cancer Immunology, Immunotherapy : CII|August 22, 2018
IL-10 inducible CD8<sup>+</sup> regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cellsJulian Plaumann, Melanie Engelhardt, Mohamed H S Awwad, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 25, 2014
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasoneTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Experimental Hematology|March 30, 2006
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myelomaMichael Hundemer, Stefanie Schmidt, Maud Condomines, et al.
Cell Reports Methods|December 1, 2022
A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myelomaTobias Dittrich, Sebastian Köhrer, Martin Schorb, et al.
British Journal of Haematology|May 24, 2022
Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damageMarkus Wennmann, Hartmut Goldschmidt, Jennifer Mosebach, et al.
Blood|June 19, 2012
Clinical and prognostic role of annexin A2 in multiple myelomaAnja Seckinger, Tobias Meissner, Jérôme Moreaux, et al.
Plos One|January 4, 2014
The glycome of normal and malignant plasma cellsThomas M Moehler, Anja Seckinger, Dirk Hose, et al.
Genes, Chromosomes & Cancer|September 25, 2004
Duplication of chromosome arms 9q and 11q: evidence for a novel, 14q32 translocation-independent pathogenetic pathway in multiple myelomaPeter Liebisch, Daniel Scheck, Seiichi Alvise Erné, et al.
European Journal of Haematology|October 18, 2006
Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantationJens Klaus, Doris Herrmann, Iris Breitkreutz, et al.
Blood|December 13, 2012
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenanceAnnemiek Broyl, Rowan Kuiper, Mark van Duin, et al.
Pageof 54

Showing results (221-230 of 539) with videos related to

Sort By:
Pageof 54
Cancer Immunology, Immunotherapy : CII|August 22, 2018
IL-10 inducible CD8<sup>+</sup> regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cellsJulian Plaumann, Melanie Engelhardt, Mohamed H S Awwad, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 25, 2014
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasoneTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Experimental Hematology|March 30, 2006
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myelomaMichael Hundemer, Stefanie Schmidt, Maud Condomines, et al.
Cell Reports Methods|December 1, 2022
A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myelomaTobias Dittrich, Sebastian Köhrer, Martin Schorb, et al.
British Journal of Haematology|May 24, 2022
Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damageMarkus Wennmann, Hartmut Goldschmidt, Jennifer Mosebach, et al.
Blood|June 19, 2012
Clinical and prognostic role of annexin A2 in multiple myelomaAnja Seckinger, Tobias Meissner, Jérôme Moreaux, et al.
Plos One|January 4, 2014
The glycome of normal and malignant plasma cellsThomas M Moehler, Anja Seckinger, Dirk Hose, et al.
Genes, Chromosomes & Cancer|September 25, 2004
Duplication of chromosome arms 9q and 11q: evidence for a novel, 14q32 translocation-independent pathogenetic pathway in multiple myelomaPeter Liebisch, Daniel Scheck, Seiichi Alvise Erné, et al.
European Journal of Haematology|October 18, 2006
Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantationJens Klaus, Doris Herrmann, Iris Breitkreutz, et al.
Blood|December 13, 2012
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenanceAnnemiek Broyl, Rowan Kuiper, Mark van Duin, et al.
Pageof 54